Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01349036 · ClinicalTrials.gov registry record · Phase 2
A Phase 2 Study of PLX3397 in Patients With Recurrent Glioblastoma
A Phase 2 study, sponsored by Daiichi Sankyo.
- Terminated
- Registry status
- Phase 2
- Development phase
- 38
- Enrollment target
NCT01349036 is a Phase 2 study that was terminated before completion, run by Daiichi Sankyo. The registered enrollment target is 38 participants.
The verdict
NCT01349036, a Phase 2 study, was terminated before completion, sponsored by Daiichi Sankyo.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 38 participants
- Enrollment target
Study Summary
The objective of this study is to evaluate the response of subjects with recurrent glioblastoma to continuous therapy of PLX3397.
Interventions
- DRUG PLX3397
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2011-12-03 |
| Est. Completion | 2013-11-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01349036
The ClinicalTrials.gov registry entry for NCT01349036 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 38 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Daiichi Sankyo, which has 236 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which PLX3397 is the first listed.
NCT01349036 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01349036 about?
NCT01349036 is a clinical study titled "A Phase 2 Study of PLX3397 in Patients With Recurrent Glioblastoma". The objective of this study is to evaluate the response of subjects with recurrent glioblastoma to continuous therapy of PLX3397.
What is the current status of trial NCT01349036?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 38 participants. The study started on 2011-12-03. Estimated completion is 2013-11-05.
What interventions are being tested in trial NCT01349036?
The interventions under investigation include: PLX3397 (DRUG).
Who is sponsoring clinical trial NCT01349036?
This trial is sponsored by Daiichi Sankyo, which has 236 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.